PHILOGEN SPA (PHIL.MI) Stock Price & Overview
BIT:PHIL • IT0005373789
Current stock price
The current stock price of PHIL.MI is 19.98 EUR. Today PHIL.MI is down by -0.1%. In the past month the price decreased by -12.37%. In the past year, price decreased by -2.54%.
PHIL.MI Key Statistics
- Market Cap
- 584.215M
- P/E
- 17.53
- Fwd P/E
- 15.99
- EPS (TTM)
- 1.14
- Dividend Yield
- 3.50%
PHIL.MI Stock Performance
PHIL.MI Stock Chart
PHIL.MI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PHIL.MI. When comparing the yearly performance of all stocks, PHIL.MI is a bad performer in the overall market: 80.1% of all stocks are doing better.
PHIL.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to PHIL.MI. While PHIL.MI has a great health rating, its profitability is only average at the moment.
PHIL.MI Earnings
PHIL.MI Forecast & Estimates
8 analysts have analysed PHIL.MI and the average price target is 26.52 EUR. This implies a price increase of 32.73% is expected in the next year compared to the current price of 19.98.
For the next year, analysts expect an EPS growth of 14.73% and a revenue growth 112.03% for PHIL.MI
PHIL.MI Groups
Sector & Classification
PHIL.MI Financial Highlights
Over the last trailing twelve months PHIL.MI reported a non-GAAP Earnings per Share(EPS) of 1.14. The EPS increased by 255.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 58.33% | ||
| ROA | 28.81% | ||
| ROE | 36.49% | ||
| Debt/Equity | 0.08 |
PHIL.MI Ownership
PHIL.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 29.43 | 42.202B | ||
| 1AE | ARGENX SE | 29.42 | 42.19B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.117B | ||
| ABVX | ABIVAX SA | N/A | 8.555B | ||
| 2X1 | ABIVAX SA | N/A | 8.555B | ||
| GLPG | GALAPAGOS NV | N/A | 1.608B | ||
| GXE | GALAPAGOS NV | N/A | 1.607B | ||
| NANO | NANOBIOTIX | N/A | 1.238B | ||
| PHARM | PHARMING GROUP NV | 48.82 | 1.036B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.007B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 975.338M | ||
| PHGN | PHARMING GROUP NV | 45.96 | 975.297M | ||
| IVA | INVENTIVA SA | N/A | 939.888M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About PHIL.MI
Company Profile
Philogen SpA engages in the engineering and clinical development of lead products capable of targeting angiogenesis. The company is headquartered in Sovicille, Siena and currently employs 193 full-time employees. The company went IPO on 2021-03-03. The firm develops products and technologies for the diagnosis and therapy of serious human diseases. The company focuses mainly on discovering and developing targeted anti-cancer drugs, using high-affinity ligands for tumor markers. These ligands are identified through Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries technologies. The Company’s products primarily address applications in the oncology field, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. The company has four anti-cancer antibody derivatives in clinical studies, one of which has completed a Phase III trial. The firm is active in the Discovery Unit through its subsidiary Philochem AG.
Company Info
IPO: 2021-03-03
PHILOGEN SPA
Via Bellaria, 35
Sovicille SIENA IT
Employees: 201
Phone: 39057717816
PHILOGEN SPA / PHIL.MI FAQ
What does PHIL do?
Philogen SpA engages in the engineering and clinical development of lead products capable of targeting angiogenesis. The company is headquartered in Sovicille, Siena and currently employs 193 full-time employees. The company went IPO on 2021-03-03. The firm develops products and technologies for the diagnosis and therapy of serious human diseases. The company focuses mainly on discovering and developing targeted anti-cancer drugs, using high-affinity ligands for tumor markers. These ligands are identified through Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries technologies. The Company’s products primarily address applications in the oncology field, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. The company has four anti-cancer antibody derivatives in clinical studies, one of which has completed a Phase III trial. The firm is active in the Discovery Unit through its subsidiary Philochem AG.
What is the current price of PHIL stock?
The current stock price of PHIL.MI is 19.98 EUR. The price decreased by -0.1% in the last trading session.
Does PHIL stock pay dividends?
PHILOGEN SPA (PHIL.MI) has a dividend yield of 3.5%. The yearly dividend amount is currently 0.
What is the ChartMill technical and fundamental rating of PHIL stock?
PHIL.MI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Which stock exchange lists PHIL stock?
PHIL.MI stock is listed on the Euronext Milan exchange.
What is the GICS sector and industry of PHIL stock?
PHILOGEN SPA (PHIL.MI) operates in the Health Care sector and the Biotechnology industry.